The TRAIN-HEART consortium, funded by the European Commission (2019-2023), is made up to train a league of 15 promising fellows that harness novel insights in the pathogenesis of ischemic heart failure, study the therapeutic potential of existing RNA therapeutics and improve its efficacy by the design of novel drug delivery systems.


TRAIN-HEART brings together leading academic teams and (biotech) companies covering various disciplines ranging from fundamental research to clinical pharmacology and gene therapy to drug delivery applications, have teamed up in the European Union.

Research Programme

The TRAIN-HEART network aims to gain viable insight in the pathogenesis of ischemic heart failure which will serve as a basis for drug discovery and drug delivery efforts that aim to therapeutically target specific molecules and mechanisms within cardiomyocytes for the treatment of ischemic heart failure.  


If you have any questions you can fill in the form or mail us directly:


Patient engagement in scientific research

The European Society of Cardiology and Harteraad, both partners in the TRAIN-HEART network, focus on the close involvement of patients in cardiovascular research.


A British Heart Foundation - King's College London Centre Technology Workshop with Professor Mauro Giacca

Presenter: Professor Mauro Giacca

Title: High throughput screening


King's College publishes on RNAemia and proteome biomarker risk stratification in intensive care unit patients with COVID-19

In this paper, the group of Prof. Mayr at King’s College London assessed RNAemia, antibody response against SARS-CoV-2 and proteomic profiles in serial blood samples from COVID-19 patients admitted to two Intensive Care Units.


Interesting review published by Deepak Balamurali on the current ncRNA databases relevant to cardiovascular research.

Review paper: Non-Coding RNA Databases in Cardiovascular Research.

Authors: Deepak Balamurali and  Monika Stoll (Maastricht University).


12th Annual RNA Therapeutics Virtual Conference (10-11 Febr 2021)

This 2021 conference is set to explore the latest developments in RNA delivery agents and RNA-based therapeutics with the latest case studies on advanced mRNA technologies, oligonucleotide delivery, therapeutic applications and future trends and innovations.